Systematic review of the Bedaquiline, Pretomanid, and Linezolid (BPaL) Regimen for Drug- Resistant Tuberculosis

Drug-resistant tuberculosis (TB) poses a significant global health challenge, demanding effective and innovative treatment strategies. The Bedaquiline, Pretomanid, and Linezolid (BPaL) regimen has emerged as a promising approach in the fight against multidrug-resistant and extensively drug-resistant TB. This systematic review synthesizes evidence from 30 selected studies to comprehensively evaluate the efficacy, safety, patient adherence, regional variations, and expert opinions surrounding the BPaL regimen. Our findings indicate that the BPaL regimen demonstrates promise in achieving positive treatment outcomes for drug-resistant TB patients. However, concerns regarding its safety profile, patient adherence, and regional variations emphasize the need for careful consideration and vigilant monitoring. Expert insights provide valuable guidance for optimizing the clinical use of the BPaL regimen. This review contributes to the ongoing discourse on effective treatment strategies for drug-resistant TB, with the goal of improving patient outcomes and global TB control efforts.